19.08.2025 • Sponsored • WhitepaperYMCBioprocessingOligonucleotides

Oligonucleotide Impurity Analysis Using Hydrophilic Interaction Chromatography (HILIC)

Download this complimentary how-to guide today!

Whitepaper cover
© Wiley

This how-to guide aims to provide scientists with comprehensive information on oligonucleotide impurity analysis using HILIC, empowering you to advance your research in this field.

What you will learn about:

  • Optimization strategies for mobile phase and gradient conditions to enhance oligonucleotide impurity analysis using HILIC
  • The integration of HILIC with mass spectrometry (MS) for precise identification and characterization of impurities
  • Techniques to address sensitivity challenges, including reducing adducts and adjusting flow rates
  • Troubleshooting common issues such as poor resolution and irreproducible retention in oligonucleotide impurity analysis

More Information

Oligonucleotides, synthetic DNA/RNA strands used in research and therapeutics, are subject to synthesis errors and degradation that can lead to impurities like shortmers and side reactions. Traditional analytical techniques, such as ion-pairing reversed-phase chromatography (IP-RP) and anion exchange chromatography (AEX), have limitations in terms of sensitivity, selectivity, and mass spectrometry compatibility. In contrast, hydrophilic interaction chromatography (HILIC) has emerged as a powerful method, offering high-resolution separation and compatibility with mass spectrometry for effective impurity profiling.

Access

Click here to register for access to this How-To Guide!

Register Now!

Company

YMC Europe GmbH



Germany

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read